Remove tag predictive-genetics
article thumbnail

‘Click’ chemistry used to tag proteins made by cancer cells 

Drug Discovery World

Biomarkers are valuable tools in diagnosing disease or predicting treatment outcomes, but they are challenging to find. . The new method involves adding chemical tags to sugar molecules which are added to cells. The researchers genetically modify the cell type they want to study, so that only this type adds the sugar to its proteins.

Protein 52
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

Chimeric antigen receptor T-cell (CAR-T) therapies are the only genetically modified cell therapies to have received regulatory approval, and they are currently utilised in relapsed/refractory settings. There were also personalised care-related unmet needs identified, and this included the need for better predictive biomarkers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sarepta’s Elevidys Reaches Finish Line as First Gene Therapy Approved for Duchenne Muscular Dystrophy

XTalks

DMD is a rare genetic disorder that leads to progressive muscle degeneration and weakness. million price tag of Elevidys, a one-time gene therapy. It primarily affects boys, affecting approximately one in 3,300 to 3,600 male births worldwide. In a media call, Sarepta CEO Douglas Ingram revealed the $3.2

article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S.